Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches

Biochem Pharmacol. 2020 Dec:182:114225. doi: 10.1016/j.bcp.2020.114225. Epub 2020 Sep 19.

Abstract

In the Fall of 2019 a sudden and dramatic outbreak of a pulmonary disease (Coronavirus Disease COVID-19), due to a new Coronavirus strain (i.e., SARS-CoV-2), emerged in the continental Chinese area of Wuhan and quickly diffused throughout the world, causing up to now several hundreds of thousand deaths. As for common viral infections, the crucial event for the viral life cycle is the entry of genetic material inside the host cell, realized by the spike protein of the virus through its binding to host receptors and its activation by host proteases; this is followed by translation of the viral RNA into a polyprotein, exploiting the host cell machinery. The production of individual mature viral proteins is pivotal for replication and release of new virions. Several proteolytic enzymes either of the host and of the virus act in a concerted fashion to regulate and coordinate specific steps of the viral replication and assembly, such as (i) the entry of the virus, (ii) the maturation of the polyprotein and (iii) the assembly of the secreted virions for further diffusion. Therefore, proteases involved in these three steps are important targets, envisaging that molecules which interfere with their activity are promising therapeutic compounds. In this review, we will survey what is known up to now on the role of specific proteolytic enzymes in these three steps and of most promising compounds designed to impair this vicious cycle.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use*
  • COVID-19 / enzymology*
  • COVID-19 Drug Treatment
  • Drug Delivery Systems
  • Humans
  • Peptide Hydrolases / metabolism*
  • Protease Inhibitors / therapeutic use*
  • Virus Replication

Substances

  • Antiviral Agents
  • Protease Inhibitors
  • Peptide Hydrolases